Breast Cancer Test (practitioners) USA - geneType™
menu

Screening for hereditary genetic disease is not enough

The Problem

While screening for pathogenic variants (like BRCA1/2) can be an important first step

  • Most women don’t qualify for BRCA1/2testing based on their family history status, and
  • Most women who do qualify for testing will come back with negative results

The Solution

geneType™ predicts your patient’s chance of developing breast cancer based on a combination of risk factors.

Identify more at-risk women than hereditary testing alone.

Once identified, your at-risk* patient has more risk-reduction and supplemental screening recommendations available to her.

*at-risk women are defined by guideline-driven, actionable thresholds; 20% lifetime risk and 1.67% or 3% 5-year risk scores1,6,8,9

Sporadic disease is the most commonly diagnosed form of breast cancer, meaning these women don’t have significant family history nor are they pathogenic variant carriers at diagnosis!

geneType™ improves upon traditional risk assessment.

Common genetic markers are genotyped to generate a polygenic risk score to which traditional clinical risk factors are combined

Personalized risk scores*: remaining lifetime risk 5-year risk

The future of risk stratification is here.

Click below to learn more about the common genetic markers in geneType’s polygenic risk scores.

geneTypes common genetic markers

The value of an integrated risk assessment

One in 200 women are positive for a hereditary breast cancer associated pathogenic variant.
One in 5 women will have a combination of risk factors that put them at an actionable, increased risk.*

*using established clinical thresholds 5-year risk threshold of 1.67% or 3%; lifetime risk threshold of 20%

Proactively identify and manage all women at increased risk of developing breast cancer

Know her risk.
Manage her risk.

By knowing her personalized risk of breast cancer you can tailor your risk-reduction recommendations.

Risk reduction* options include:

  • Mammography (digital, tomosynthesis)
  • MRI
  • Ultrasound
  • Breast cancer prevention specialist referral
  • Medication aromatase inhibitors; selective estrogen receptor modulators
  • Diet and exercise modifications
  • Smoking cessation
  • Alcohol consumption modification

* based on NCCN, ASCO, USPSTF recommendations

Nearly half of all screen-age women have dense breast tissue

The Problems

Mammographically dense breast tissue increases a woman’s risk of developing breast cancer.

The majority of US states require breast density notification.

It is not feasible to provide additional screening to all women who have dense breast tissue.

The Solution

But it is possible to risk stratify that group of women.

geneType™ incorporates breast density status into its risk assessment model.

Understand your patient’s comprehensive risk of breast cancer in the context of her breast density status and other important risk factors.

The geneType™ patient

geneType™ for Breast Cancer is appropriate for:

  • Women
  • Aged 30 years or older

geneType™ is not appropriate for women with a personal history of breast cancer, or those who are positive for a pathogenic variant associated with hereditary breast cancer.

Testing is simple

Step 1

Register as a provider; our team will provide clinical education and other resources as needed.

We will send kits to your clinic to have on hand.

Step 2

Discuss geneType™ with your patient.

Would geneType™ help them qualify for additional risk reduction strategies?

Step 3

Complete the Test Requisition form, collect a saliva sample from the patient with the collection kit provided and return both to Rhythm.

You will have the option to use a paper requisition, or a secure, compliant portal to complete the ordering process.

Step 4

Leave the rest to us.

We will notify you when your patient’s results are ready.

You will have the option to request a consult with a genetic counsellor, whether to review your patient’s results and/or to follow-up with your patient, as needed.

Register as a geneType™ provider

Simple actionable insights

Straightforward interpretation:

  • Your patient’s absolute risk scores
    • Five-year risk
    • Remaining lifetime-risk
  • Interpretation of the risk scores in the context of current guidelines
  • Types of screening and risk reduction interventions relevant to her risk category

Simple communication to your patient:

  • Risk scores presented in the context of other women her age
  • Types of screening and risk reduction interventions relevant to her risk category
  • Information about modifiable breast cancer risk factors
Sample patient report

Do you have questions?
We have answers.

If we haven’t answered your question, Contact us directly.

How does this fit in with the guidelines?

The guidelines recommend you assess risk.

Women 35 and older are eligible for breast cancer risk reducing options based on their 5-year risk scores, as recommended by the United States Preventative Services Taskforce (USPSTF), National Comprehensive Cancer Network (NCCN) and American Society of Cinical Ongology (ASCO). Furthermore, supplemental surveillance such as MRI is available for patients with lifetime risk scores greater than 20%, as recommended by NCCN, American College of Radiology (ACR), The American Society of Breast Surgeons (ASBrS).

To see if your patient is eligible for any of the availbale risk reduction or surveillance options, it is important to assess her risk.

If my patient already gets her regular mammogram, is there benefit to know her breast cancer risk score?

Yes! A breast cancer risk score (lifetime and 5-year risk) can be used to tailor a screening and risk-reduction plan for your patient. If she is at increased risk, this may entail supplemental screening options. She also may be eligible for risk reducing medication.

I already order hereditary genetic germline gene panels for my patients' breast cancer risk, why should I order geneType?

The geneType™ test does NOT look for hereditary germline pathogenic variants. We are a risk assessment for your patients that either do not qualify for hereditary testing, or who have received negative germline hereditary cancer panel results. Hereditary genetic testing is the tip of the iceberg in breast cancer risk assessment. Although impactful, it only affects a small proportion of your patient population. The remainder of your patient population is still at risk of sporadic (non-hereditary) breast cancer; geneType™ can help identify a group of at-risk patients that may have otherwise “flown under your radar.”

If my patient does not have an elevated risk on the test, does that mean she can skip her mammogram screenings?

No!

geneType™ for Breast Cancer results will indicate whether the patient is at increased or average risk.

If she is at average risk, it is still important to follow the recommended screening guidelines for women of her age.

Is this test reimbursed by insurance?

No. At this time geneType™ is a self-pay test. However, your patient may use FSA/HSA to pay for the test.

Are you ready to get started with geneType?

The first step is to trial geneType™ at your practice

Contact us

*Patient eligibility dependent on personal medical history, age and sex

Interested in ordering more than one disease? Order geneType™ Multi-Test.

The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only. 

References
  1. American Cancer Society. URL: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
  2. van der Groep P et al. Cell Oncol (Dordr) 2011;34:71 -88.
  3. Spaeth E, et al. Cancer Prevention Research. 2023 doi: 10.1158/1940-6207.CAPR-22-0460
  4. Allman R, et al. SNPs and breast cancer risk prediction for African American and Hispanic women. Breast Cancer Res Treat. 2015 Dec;154(3):583-9.
  5. Allman R, et al. Breast Cancer Research and Treatment 2023 doi: 10.1007/s10549-022-06834-7.
  6. Medication Use to Reduce Risk of Breast Cancer, United States Preventative Services Task Force. JAMA. 2019; 322(9):857-867
  7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines); Breast Cancer Screening and Diagnosis. Version 1.2021- April 2022.
  8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines); Breast Cancer Risk Reduction. Version 1.2022 – April 2022
  9. Use of Endocrine Therapy for Breast Cancer Risk Reduction. Journal of Clinical Oncology 37, no. 33 (November 20, 2019) 3152-3165.
  10. Monticciolo D et al. Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk: Update from the ACR and Society of Breast Imaging. J Am Coll Radiol. 2021 Sep;18(9):1280-1288.

Accredited For Compliance With NPAAC Standards And ISO 15189